En
- Fr

Investors
Our business units
Message from the Chairman
Oncodesign shares
Regulated Information [FR]
General meetings
Analysts coverage
Investor Day
Letters to our shareholders
Financial news
Oncodesign
Careers
Oncodesign is recruiting!
HR-policy
Our employees
Professional Equality Index
Resources
Scientific resources
Webinar
Posters
Scientific publications
Press
Press release
Press coverage
Media kit
News

Oncodesign

Service
Biotech
Artificial intelligence
Innovation technologies
Homing program
About us
Contact us

Investors
Careers
Resources

More results...

Generic filters

Hidden label

Drug Discovery Service

Integrated or stand alone Drug Discovery services (from hit findings to IND), to discover and evaluate the therapies of tomorrow together.

Discover

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation

Read the press release

Participate in research and development programs

Value creation through innovative technologies & R&D partnerships

Discover

Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate

Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.

Read the press release

Artificial intelligence for therapeutic innovation

For Oncodesign, artificial intelligence (AI) is a powerful tool for accelerating and making drug development more reliable.

Discover how Oncodesign uses AI

Data use for Drug Discovery: InterSystems and Oncodesign Join Forces

Optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read the press release

Our innovation technologies, a continuum from the molecule to the patient

For more than 25 years, Oncodesign has been investing in precision medicine innovation technologies, which are essential from the very first stages of the Drug Discovery process.

Discover

Oncodesign, experts in precision medicine

Oncodesign’s mission is to discover new innovative therapies that are effective against cancers and serious diseases with no known treatments.

Discover

Letters to our shareholders

02/11/2020

Letter to our shareholders – November 2020

“Hunting in packs, a collaborative commercial approach hard-wired into Oncodesign’s genes” – Philippe GENNE, President and CEO of Oncodesign

Download our letter

02/04/2020

Letter to our shareholders – April 2020

Here is our April 2020 issue which details the new organization of the Group into 3 Business Units. Interviews and articles on the menu. Anatomy of the new face of Oncodesign: BU Service, BU Biotech & BU Artificial Intelligence. Without forgetting the editorial by Ph. Genne entitled “how much is…

Download our letter

02/06/2019

Letter to our shareholders – June 2019

“The health sector is in great need of innovations, & will continue to be for a long time yet” says Philippe Genne, CEO & founder, Oncodesign Biotechnology.

Download our letter

02/11/2018

Letter to our shareholders – November 2018

“I urge you all to stay aboard and keep your eyes firmly fixed on the future: we believe in it” says Philippe Genne, CEO & founder, Oncodesign Biotechnology.

Download our letter